## Natco Pharma Limited (NATCOPHARM) Investment Report - December 20, 2024

**1. Company Overview:**

Natco Pharma Limited (NATCOPHARM) is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since December 27, 1995.  It operates within the Pharmaceuticals industry and focuses on the development and marketing of generic drugs.  The company's positioning within the sector is characterized by its focus on affordable generic medications.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹1,425.15       | Closed at ₹1,416.95; Pre-open at ₹1,480.5                        |
| Percentage Change (PChange) | -3.50%          | Significant negative daily change                                    |
| Pre-Open Activity          | ₹1,480.5 (High) | Shows initial positive sentiment, but this was not sustained.       |
| Week High                   | ₹1,639          | High price point reached during the week.                           |
| Week Low                    | ₹755            | Significant low price point reached during the week.                |
| VWAP                        | ₹1,444.28       | Volume Weighted Average Price for the day.                          |
| Sector PE                   | 13.61           | Price-to-Earnings ratio for the sector.                             |
| Symbol PE                   | 13.61           | Price-to-Earnings ratio for NATCOPHARM.                            |
| Delivery Percentage         | 45.36%          | Relatively high delivery percentage, suggesting some conviction.     |
| Market Depth                | Low              | Order book data shows low buy and sell quantities at various price points.  This suggests low liquidity.|


**3. Financial Performance:**

The following table summarizes Natco Pharma's financial performance over the past five quarters.  Note that data is a mix of audited and unaudited figures.  Profitability is significantly lower in the last two quarters.

| Quarter      | Revenue (₹) | Expenses (₹) | Profit After Tax (₹) | Diluted EPS (₹) |
|--------------|-------------|-------------|-----------------------|-----------------|
| Q3 FY24       | 134,400     | 54,710      | 66,110                 | 36.91            |
| Q2 FY24       | 127,670     | 51,870      | 63,630                 | 35.53            |
| Q1 FY24       | 100,070     | 56,820      | 34,910                 | 19.49            |
| Q4 FY23       | 65,480      | 43,120      | 19,200                 | 10.72            |
| Q3 FY23       | 95,520      | 53,120      | 36,020                 | 20.11            |


**Key Financial Ratios (Further analysis needed with complete financial statements):**  The provided data lacks sufficient information to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  These would be crucial for a comprehensive financial health assessment.  The significant drop in profit after tax and EPS in Q1 FY24 and Q4 FY23 compared to previous quarters is a major concern.

**4. Corporate Actions and Announcements:**

Natco Pharma has declared several interim dividends in the past year, with the most recent being ₹1.50 per share (ex-date November 27, 2024).  The company also held its Annual General Meeting (AGM) in September 2024.  Recent announcements primarily relate to loss/duplicate share certificates and updates, suggesting no major strategic shifts.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023  | 49.71                        | 50.29      | 0.00                             | 100.00    |
| 31-Dec-2023  | 49.71                        | 50.29      | 0.00                             | 100.00    |
| 31-Mar-2024  | 49.71                        | 50.29      | 0.00                             | 100.00    |
| 30-Jun-2024  | 49.71                        | 50.29      | 0.00                             | 100.00    |
| 30-Sep-2024  | 49.62                        | 50.38      | 0.00                             | 100.00    |

Promoter shareholding has slightly decreased in the last quarter, while public shareholding has increased correspondingly. This is a minor shift and doesn't indicate a major concern.

**6. Volatility and Risk Assessment:**

The stock has shown significant volatility in the recent past, with a week high of ₹1,639 and a week low of ₹755.  The CM Annual Volatility of 37.45% indicates high risk.  The low market depth further exacerbates this risk, making it difficult to enter or exit positions quickly without significantly impacting the price.

**7. Advantages of Buying the Stock:**

* Consistent dividend payouts.
* Established presence in the pharmaceutical sector.

**8. Disadvantages and Risks:**

* High volatility and risk.
* Declining profitability in recent quarters.
* Low market depth and liquidity.
* Lack of sufficient data for comprehensive financial analysis.

**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The recent price drop and high volatility make a short-term investment risky.  The low market depth makes it difficult to exit quickly if the price continues to fall.

* **Medium-term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends on the company's ability to reverse the declining profitability trend.  Further analysis of the complete financial statements is needed to assess the sustainability of the business model.

* **Long-term (1 year and beyond): Don't Buy.**  While the company has an established presence, the recent financial performance raises serious concerns about its long-term sustainability.  More information is needed to assess the long-term prospects.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial Health: 4/10 (Declining profitability is a major concern)
* Market Performance: 3/10 (High volatility and recent price drop)
* Volatility and Risk: 2/10 (High volatility and low liquidity)
* Corporate Actions & Governance: 7/10 (Consistent dividend payouts, but limited information on governance)
* Shareholding Patterns: 6/10 (Minor shift in shareholding, relatively stable)

**Analysis Score (out of 10): 7/10**

* Completeness and Utilization of Data: 7/10 (Most data used, but some key ratios are missing due to incomplete financial data)
* Accuracy and Clarity of Analysis: 8/10 (Analysis is clear and well-structured)
* Professional Formatting: 9/10 (Report is well-formatted and easy to read)


**11. Professional Recommendation Summary:**

Based on the available data, NATCOPHARM presents a high-risk investment.  The declining profitability and high volatility outweigh the advantages of consistent dividend payouts.  A "Don't Buy" recommendation is given for both short-term and long-term horizons.  A "Hold" recommendation is given for medium-term only if you already own the stock, pending further analysis of complete financial statements to assess the sustainability of the business model.  More comprehensive financial data is crucial for a more accurate and confident investment recommendation.
